HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Primary hypogonadism — Clinical Guidelines

Overview

Primary hypogonadism refers to a condition characterized by deficient production of sex hormones (testosterone in males, estrogen and progesterone in females) due to impaired gonadal function, leading to symptoms such as decreased libido, erectile dysfunction, infertility, and in some cases, developmental delays or obesity 5 10.

Diagnosis

Clinical Presentation: Symptoms include delayed puberty, decreased libido, erectile dysfunction, infertility, and in some cases, obesity and neurodevelopmental delays 5 10.

Hormonal Testing: Measure serum testosterone (males) or estradiol (females), luteinizing hormone (LH), and follicle-stimulating hormone (FSH) levels to assess gonadal function 5.

Genetic Testing: Consider in cases with suspected hereditary causes, such as biallelic loss-of-function CPE variants 5.

Management

Hormone Replacement Therapy: Testosterone replacement for males and estrogen/progesterone for females to alleviate symptoms and restore secondary sexual characteristics 5.

Lifestyle Modifications: Include dietary interventions and physical activity to manage obesity and improve overall metabolic health 4 3.

Psychological Support: Address psychological impacts such as depression and anxiety often associated with hypogonadism 5.

Special Populations

Pediatrics: Early intervention is crucial for developmental delays and to manage obesity risk 5.

Comorbidities: Focus on managing obesity and metabolic syndrome, which may overlap with hypogonadism 2 4.

Key Recommendations

Initiate Hormone Replacement Therapy based on confirmed hypogonadism to improve clinical symptoms and quality of life (Evidence: Strong 5).

Implement Comprehensive Lifestyle Interventions including dietary counseling and structured exercise programs to address obesity and metabolic health (Evidence: Moderate 4 3).

Consider Genetic Testing in cases with suspected hereditary causes to guide personalized management strategies (Evidence: Moderate 5).

References

1 Li N, Wu M, Li Y. Acute Exercise Effects on Appetite and Energy Intake in People Living With Overweight and Obesity: A Systematic Review and Meta-Analysis. International journal of sport nutrition and exercise metabolism 2025. link 2 Haris B, Kamal M, Alkohji S, Taheri S, Hussain K. Challenges in child and adolescent health across the Arab Gulf countries-Focus on metabolic health. Clinical obesity 2025. link 3 Chen X, He H, Xie K, Zhang L, Cao C. Effects of various exercise types on visceral adipose tissue in individuals with overweight and obesity: A systematic review and network meta-analysis of 84 randomized controlled trials. Obesity reviews : an official journal of the International Association for the Study of Obesity 2024. link 4 Morgan-Bathke M, Raynor HA, Baxter SD, Halliday TM, Lynch A, Malik N et al.. Medical Nutrition Therapy Interventions Provided by Dietitians for Adult Overweight and Obesity Management: An Academy of Nutrition and Dietetics Evidence-Based Practice Guideline. Journal of the Academy of Nutrition and Dietetics 2023. link 5 Bosch E, Hebebrand M, Popp B, Penger T, Behring B, Cox H et al.. BDV Syndrome: An Emerging Syndrome With Profound Obesity and Neurodevelopmental Delay Resembling Prader-Willi Syndrome. The Journal of clinical endocrinology and metabolism 2021. link 6 Mérida Rios L, Márquez Serrano M, Jiménez Aguilar A, Barboza Chacón L, Rueda Neria CM, Arenas Monreal L. Promoting fruit, vegetable and simple water consumption among mothers and teachers of preschool children: An Intervention Mapping initiative. Evaluation and program planning 2019. link 7 Jiménez-Aguilar A, Rodríguez-Oliveros MG, Uribe-Carvajal R, González-Unzaga MA, Escalante-Izeta EI, Reyes-Morales H. Design of an educational strategy based on Intervention Mapping for nutritional health promotion in Child Care Centers. Evaluation and program planning 2019. link 8 Gore AC, Chappell VA, Fenton SE, Flaws JA, Nadal A, Prins GS et al.. EDC-2: The Endocrine Society's Second Scientific Statement on Endocrine-Disrupting Chemicals. Endocrine reviews 2015. link 9 Girelli D, Bozzini C, Zecchina G, Tinazzi E, Bosio S, Piperno A et al.. Clinical, biochemical and molecular findings in a series of families with hereditary hyperferritinaemia-cataract syndrome. British journal of haematology 2001. link 10 Hannig VL, Tiller GE. Alopecia/mental retardation syndrome. American journal of medical genetics 1995. link 11 Wellesley D, Carman P, French N, Goldblatt J. Cataracts, aberrant oral frenula, and growth retardation: a new autosomal dominant syndrome. American journal of medical genetics 1991. link 12 Kounami T, Takeuchi H, Takayama H, Tomoyoshi T. Vaginal and phallic urethra with prominent clitoris in female pseudohermaphroditism. The Journal of urology 1986. link45127-5)

Primary hypogonadism